Loading
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Regular session
$1.35
+$0.01 · +0.75%
Regular session · ET · Market data may be delayed.
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Day range
Current $1.35
52-week range
Current $1.35
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
44
Fair Value
Sentiment
60
Mixed
Risk
66
High Risk
Momentum
31
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Day range
Current $1.35
52-week range
Current $1.35
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Research and development | 3.63M USD | 1.41M USD | 6.46M USD | 7.45M USD | 5.2M USD |
| Selling, general, and administrative | 5.14M USD | 3.08M USD | 3.48M USD | 7.42M USD | 7.12M USD |
| Operating expenses | 8.77M USD | 4.5M USD | 9.94M USD | 14.87M USD | 12.32M USD |
| Interest income | 1.08K USD | — | — | — | — |
| Interest expense | −6.62K USD | 18.03K USD | 10.1K USD | 7.7K USD | 46.52K USD |
| Depreciation and amortization | 110.74K USD | 50.74K USD | 50.74K USD | 23.07K USD | 3.55K USD |
| Operating income | −8.77M USD | −4.5M USD | −9.94M USD | −14.87M USD | −12.32M USD |
| Net income | −8.77M USD | −4.51M USD | −9.95M USD | −14.88M USD | −12.36M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | May 12, 2025 | 1:9 | — | — |
Stock split | Jul 16, 2024 | 1:10 | — | — |
Stock split | Oct 31, 2023 | 1:15 | — | — |
Effective May 12, 2025
1:9
Effective Jul 16, 2024
1:10
Effective Oct 31, 2023
1:15
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
